Just a moment, the page is loading...
Browse ALL STUDIES
Keyword Search
View All Selected
Clear All
Login / Create Account
Login
Create Account
Home
About Us
Privacy Policy
Minimum System Requirements
How To Join
Mission
Data Sponsors
Researchers
How It Works
How to Request Data
Review of Requests
Data Sharing Agreement
Access to Data
Independent Review Panel
Metrics
FAQs
News
Help/Contact Us
SLE clinical and laboratory profiling to indentify best response to belimumab: results from the phase III belimumab clinical trials
Proposal
5915
Title of Proposed Research
SLE clinical and laboratory profiling to indentify best response to belimumab: results from the phase III belimumab clinical trials
Lead Researcher
Savino Sciascia
Affiliation
Center of Research of Immunopathology and Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy. MD,Center of Research of Immunopathology and Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy. MD, Consultant in Clinical Immunology
Funding Source
Potential Conflicts of Interest
Data Sharing Agreement Date
8 May 2019
Lay Summary
Systemic lupus erythematosus (SLE) is a chronic disease affecting the immune system characterized by phase of activity and alternating periods of remission. The clinical manifestations are extremely heterogeneous with multi-systemic involvement, including symptoms such as fever and malaise, as well as dermatological, musculoskeletal, renal, respiratory, cardiovascular, hematological, and neurological manifestations. Until recently, the treatment and management of SLE were based mainly on non-steroidal anti-inflammatory drugs, glucocorticoids, hydroxychloroquine, and immunosuppressive agents. Scientific progress and the rise of biologic therapies in the treatment of SLE has resulted in a significant improvement in prognosis. Nonetheless, SLE management is still challenging because of the adverse effects of conventional therapies (especially steroids), occurrence of refractory disease and non response to treatment. As we acquire a better understanding of SLE pathogenesis, we are able to correlate clinical manifestations of SLE with specific pathogenic pathways (that is, cellular and molecular mediators that could be specifically targeted). Therefore, biological therapies could become even more important in SLE management. In the future, the management of SLE could be tailored to the patient's specific manifestations and clinical characteristics by the use of specific biological therapies.Taken the above together, these observations suggest that specific SLE populations, with specific organ involvement and pathogenic manifestations would be more likely to have a better outcome when treated with specific biological therapies, such as belimumab. All the above is in line with the risen concept of the so called precision medicine, aiming to identify sub-populations of patients with specific disease profiles who might benefit at the most of a tailored therapeutic approach. In this study, we aim to investigate the effectiveness of belimumab therapy in a post-hoc analysis on the 3 randomized controlled trials BLISS-52, BLISS-76 and BLISS-SC, when considering specific populations of SLE patient, based on their clinical and laboratory manifestations. Furthermore, we aim to investigate the role of belimumab as a steroid-sparing drug in specific patients populations. This study might demonstrate and highlight a better efficacy of belimumab when treating SLE patients with specific clinical manifestations and, potentially, suggested such an approach as first line therapy in order to maximize therapeutic effect and minimize adverse ones.
Study Data Provided
[{ "PostingID": 1416, "Title": "GSK-HGS1006-C1056", "Description": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 76-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE)" },{ "PostingID": 1417, "Title": "GSK-HGS1006-C1057", "Description": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Wk Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE)" },{ "PostingID": 14488, "Title": "GSK-HGS1006-C1115", "Description": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Systemic Lupus Erythematosus (SLE)" }]
Statistical Analysis Plan
Publication Citation
© 2024 ideaPoint. All Rights Reserved.
Powered by ideaPoint.
Help
Privacy Policy
Cookie Policy
Help and Resources